海思科：子公司HSK39297片上市许可申请获受理

Core Viewpoint - Company Sichuan Haisco Pharmaceutical Co., Ltd. received a Notice of Acceptance from the National Medical Products Administration for HSK39297 tablets, which are intended for the treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1] Group 1 - The acceptance notice was issued on January 6, 2026 [1] - HSK39297 is specifically designed for adult patients with a history of not being treated with complement inhibitors [1]